FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:203-205 July 21, 1994 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Groothuis, J. R. PubMed Citation

To the Editor: We write regarding the article (Nov. 18 issue)¹ reporting the results of a multicenter clinical trial that appeared to demonstrate the efficacy of immune globulin with a high titer of antibodies against respiratory syncytial virus (RSV immune globulin), given intravenously, in preventing RSV infection of the lower respiratory tract in high-risk children. The article was accompanied by a very positive editorial². A scant two weeks later, the Blood Products Advisory Committee of the Food and Drug Administration (FDA) voted unanimously, on the basis of the same data, against recommending that this product be licensed. Although we . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Storch, G. A. (1998). Humanized Monoclonal Antibody for Prevention of Respiratory Syncytial Virus Infection. Pediatrics 102: 648-651 [Full Text]  
• Robbins, J. M., Tilford, J. M., Jacobs, R. F., Wheeler, J. G., Gillaspy, S. R., Schutze, G. E. (1998). A Number-Needed-to-Treat Analysis of the Use of Respiratory Syncytial Virus Immune Globulin to Prevent Hospitalization. Arch Pediatr Adolesc Med 152: 358-366 [Abstract] [Full Text]